Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9909944 | 1.00 | PPARG (0.91) | PPARGPPARA | |
| SCHEMBL4680723 | 0.95 | PPARA (1.00) | PPARGPPARA | |
| SCHEMBL30515134 | 0.95 | PPARA (1.00) | PPARGPPARA | |
| SCHEMBL18095652 | 0.95 | PPARA (1.00) | PPARGPPARA | |
| SCHEMBL9910077 | 0.92 | PPARG (0.87) | PPARGPPARA | |
| SCHEMBL3799289 | 0.92 | PPARG (0.87) | PPARGPPARA | |
| SCHEMBL15267315 | 0.92 | PPARG (0.87) | PPARGPPARA | |
| SCHEMBL3808617 | 0.92 | PPARG (0.87) | PPARGPPARA | |
| SCHEMBL9910024 | 0.92 | PPARG (0.87) | PPARGPPARA | |
| SCHEMBL9910103 | 0.92 | PPARG (0.87) | PPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180153859-A1 | METHODS OF TREATING OR PREVENTING COGNITIVE IMPAIRMENT USING INDANE ACETIC ACID DERIVATIVES BASED ON APOE4 GENOTYPE | T3D THERAPEUTICS, INC. (US) | 2018-06-07 | — | — | US | disclosed |
| US-20140370011-A1 | METHODS OF TREATING OR PREVENTING COGNITIVE IMPAIRMENT USING INDANE ACETIC ACID DERIVATIVES | DARA BIOSCIENCES, INC. (US) | 2014-12-18 | — | — | US | disclosed |
| US-20140086910-A1 | METHODS OF TREATING OR PREVENTING ALZHEIMER'S DISEASE USING INDANE ACETIC ACID DERIVATIVES | DARA BIOSCIENCES, INC. (US) | 2014-03-27 | — | — | US | disclosed |
| US-20120141483-A1 | METHODS OF TREATING OR PREVENTING PSORIASIS, AND/OR ALZHEIMER'S DISEASE USING INDANE ACETIC ACID DERIVATIVES | DARA BIOSCIENCES, INC. | 2012-06-07 | — | — | US | disclosed |
| US-20120141483-A1 | METHODS OF TREATING OR PREVENTING PSORIASIS, AND/OR ALZHEIMER'S DISEASE USING INDANE ACETIC ACID DERIVATIVES | DARA BIOSCIENCES, INC. | 2012-06-07 | — | — | US | disclosed |
| WO-2012074980-A2 | METHODS OF TREATING OR PREVENTING AUTOIMMUNE DISORDERS AND LIVER DISORDERS USING INDANE ACETIC ACID DERIVATIVES | DARA BIOSCIENCES, INC. (US) | 2012-06-07 | — | — | WO | disclosed |
| WO-2010141696-A1 | METHODS OF TREATING OR PREVENTING PSORIASIS, AND/OR ALZHEIMER'S DISEASE USING INDANE ACETIC ACID DERIVATIVES | DARA BIOSCIENCES, INC. (US) | 2010-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140086910-A1 | METHODS OF TREATING OR PREVENTING ALZHEIMER'S DISEASE USING INDANE ACETIC ACID DERIVATIVES | ACHE, CHAT, APP | PPARG 684/4885PPARA 368/4885 |
| US-20140370011-A1 | METHODS OF TREATING OR PREVENTING COGNITIVE IMPAIRMENT USING INDANE ACETIC ACID DERIVATIVES | CHAT, ACHE, AANAT | PPARG 596/4885PPARA 507/4885 |
| US-20180153859-A1 | METHODS OF TREATING OR PREVENTING COGNITIVE IMPAIRMENT USING INDANE ACETIC ACID DERIVATIVES BASED ON APOE4 GENOTYPE | CHRNA2, ACACA, CHAT | PPARG 988/4885PPARA 534/4885 |
| US-20120141483-A1 | METHODS OF TREATING OR PREVENTING PSORIASIS, AND/OR ALZHEIMER'S DISEASE USING INDANE ACETIC ACID DERIVATIVES | APP, MAPT, TNF | PPARG 81/4885PPARA 56/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.